Paper Details

  1. Home
  2. Paper Details

Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.

Author: ArangoCelso, LeuchtStefan, Lopez-MorinigoJavier-David

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Early-onset schizophrenia (EOS) is associated with significant disease burden and disability. This study critically compared evidence supporting EOS-approved drugs with guideline recommendations. Aripiprazole, lurasidone, molindone, risperidone, paliperidone, and quetiapine emerged as efficacious and safe options for EOS. The study highlights the need for further research on long-term outcomes such as cognition, functioning, and quality of life.
Paper Details　
Original Abstract of the Article :
Early-onset schizophrenia (EOS) - onset before age 18 - is linked with great disease burden and disability. Decision-making for EOS pharmacological treatment may be challenging due to conflicting information from evidence and guidelines and unidentified care needs may remain unmet.We searched for sy...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458343/

データ提供：米国国立医学図書館（NLM）

Early-Onset Schizophrenia: A Critical Review of Pharmacological Treatment

Early-onset schizophrenia (EOS), a debilitating mental illness that emerges before the age of 18, poses unique challenges for treatment. This research provides a critical review of the pharmacological treatment options for EOS, examining the evidence supporting approved drugs and identifying unmet needs in care. The study analyzed a comprehensive selection of systematic reviews, meta-analyses, and umbrella reviews published in PubMed over the past decade, along with five clinical guidelines from Europe, North America, and Australia.

Evidence-Based Guidance and Unmet Needs

The study found that evidence supports the efficacy of several antipsychotics, including aripiprazole, clozapine, haloperidol, lurasidone, molindone, olanzapine, quetiapine, risperidone, and paliperidone, in the treatment of EOS. However, the study also highlighted significant gaps in the evidence, with limited research focusing on key outcomes such as cognition, functioning, quality of life, suicidal behavior, mortality, and service utilization.

Improving Treatment and Reducing Disease Burden

This research underscores the critical need for further research on the long-term effects of pharmacological treatment for EOS, focusing on improving patient outcomes and addressing unmet needs. Imagine a desert landscape where the path to managing EOS is often unclear and fraught with challenges. This research provides a framework for navigating this complex terrain, seeking new solutions to reduce the burden of this debilitating illness.

Dr.Camel's Conclusion

This comprehensive review of pharmacological treatment for early-onset schizophrenia emphasizes the need for continued research and development of more effective and targeted therapies. Think of it like exploring a desert with many paths but limited resources. This research illuminates the need for continued investigation to find the best route towards improving outcomes for individuals with EOS.
Date :
  1. Date Completed 2022-09-12
  2. Date Revised 2022-09-12
Further Info :

Pubmed ID

35777418

DOI: Digital Object Identifier

PMC9458343

Related Literature

Article Analysis
・Effects of molindone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.